Clinical Evidence: What 1 Month Results Really Mean
Understanding Wegovy 1 Month Results in Clinical Context
When evaluating Wegovy 1 month results, it's crucial to understand that the first month involves dose escalation rather than maximum therapeutic effect. During weeks 1-4, patients receive the 0.25mg starter dose, which primarily helps your body adjust to the medication whilst minimising side effects. In clinical trials, patients taking Wegovy alongside diet and exercise achieved their most significant results after reaching higher maintenance doses over several months. The comparison between Wegovy and Mounjaro becomes particularly relevant here, as both medications follow different escalation schedules and mechanisms of action.
Mounjaro operates through dual GIP and GLP-1 receptor agonism, whilst Wegovy targets GLP-1 receptors specifically. Both treatments require gradual dose increases to reach therapeutic levels, meaning realistic expectations for month one focus on tolerability and initial adaptation rather than dramatic changes. Clinical evidence from the STEP trials demonstrates that Wegovy's effects build progressively, with optimal results typically observed after patients reach the 2.4mg maintenance dose around week 17 of treatment.
Wegovy vs Mounjaro Pricing: Complete Cost Comparison
EverydayMeds offers competitive pricing for both Wegovy and Mounjaro, allowing direct cost comparison for your 1 month treatment period. Wegovy 0.25mg starter doses cost £79.99 with new customer code FIRST40 applied at checkout, progressing to £94.99 for 0.5mg doses in weeks 5-8. Our Intro Duo bundle combining both starter doses costs £169.99, providing two months of initial treatment. Returning customers benefit from code DOSE25 for ongoing orders throughout their treatment journey.
Mounjaro pricing follows a different structure reflecting its distinct dosing schedule and mechanism. Both treatments represent significant monthly investments, making it essential to understand the complete cost implications before starting either option. Our transparent pricing eliminates hidden fees, with all costs clearly displayed including VAT. Payment plans and bundle options help manage the financial commitment whilst ensuring consistent treatment supply through our GPhC-registered pharmacy (#9012878).
Clinical Evidence from STEP Trials for Wegovy 1 Month Results
The landmark STEP 1 trial (Wilding et al., NEJM, 2021) provides crucial evidence about Wegovy's timeline and effectiveness. Participants achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, demonstrating the medication's long-term potential beyond initial month results. However, these outcomes required sustained treatment alongside intensive lifestyle modifications, not just the initial month of 0.25mg dosing.
STEP 5 data confirms that approximately 15.2% weight reduction can be sustained at 2 years, whilst the SELECT cardiovascular trial showed a 20% reduction in major cardiovascular events. These findings emphasise that Wegovy 1 month results represent just the beginning of a longer therapeutic journey, with optimal benefits emerging through consistent treatment and lifestyle changes over extended periods.
How Wegovy's GLP-1 Mechanism Differs from Mounjaro
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. This mechanism works by slowing gastric emptying, enhancing glucose-dependent insulin secretion, and acting on brain appetite centres to reduce food cravings. The 0.25mg starting dose begins this process gently, allowing your digestive system to adapt whilst minimising common initial side effects like nausea or digestive discomfort. Mounjaro's tirzepatide targets both GIP and GLP-1 receptors, offering dual pathway activation that may provide different therapeutic benefits. Both medications require prescription-only access and clinical assessment to ensure appropriate use alongside dietary and exercise interventions for optimal safety and effectiveness.
Ordering Process: Assessment to Delivery in 3 Steps
Beginning your Wegovy or Mounjaro journey starts with our comprehensive 3-minute online clinical assessment, covering your medical history, current medications, and weight management goals. Our qualified prescribers review your application within 3 working days (or 24 hours with express service), ensuring appropriate prescribing and safety monitoring throughout your treatment. Once approved, your medication ships via next-day cold-chain delivery, maintaining the precise 2-8°C temperature requirements essential for medication stability and effectiveness. Our GPhC-registered pharmacy (#9012878) handles all aspects of dispensing and delivery, providing ongoing support and prescription management. Regular follow-up assessments ensure continued appropriateness and safety monitoring as you progress through dose escalations and achieve your weight management objectives.
Storage and Practical Considerations for Wegovy 1 Month Results
Wegovy requires refrigeration at 2-8°C before first use, but offers superior storage flexibility with 6 weeks room temperature tolerance below 30°C once removed from the fridge. This advantage over Mounjaro's 21-day room temperature limit makes Wegovy more practical for travel or temporary storage disruptions during your first month and beyond. The FlexTouch pen delivery system provides accurate, consistent dosing with clear dose escalation from 0.25mg through to 2.4mg maintenance levels. Proper injection technique and site rotation help minimise injection site reactions whilst ensuring optimal medication absorption. Understanding these practical aspects during your first month establishes good habits for long-term treatment success and medication effectiveness.
Month-by-Month Dose Escalation: Wegovy vs Mounjaro Schedules
Wegovy 1 month results must be understood within the context of its specific dose escalation protocol, starting with 0.25mg for weeks 1-4, then progressing to 0.5mg, 1mg, 1.7mg, and finally 2.4mg maintenance dosing. This gradual increase allows your body to adapt whilst building therapeutic effectiveness over time. Mounjaro follows its own escalation schedule with different dose intervals and maximum levels, reflecting the distinct pharmacological profiles of semaglutide versus tirzepatide.
Neither medication can skip dose levels safely, making the first month primarily about establishing tolerance rather than achieving maximum therapeutic benefit. Realistic expectations for month one focus on adaptation, potential mild side effects management, and establishing consistent injection routines. Both treatments available from EverydayMeds come with comprehensive support materials and ongoing clinical guidance to optimise your experience throughout the escalation period and beyond.
Making Your Choice: Expert Clinical Guidance Available
Choosing between Wegovy and Mounjaro for optimal 1 month results requires professional clinical assessment of your individual circumstances, medical history, and treatment goals. Our prescribers evaluate factors including your BMI, comorbidities, previous weight management attempts, and lifestyle factors to recommend the most appropriate option. Both medications represent significant commitments requiring ongoing monitoring and support, making expert guidance essential for treatment success. EverydayMeds stocks both options with competitive pricing, expert clinical oversight, and comprehensive patient support throughout your weight management journey. Apply online today using discount codes FIRST40 for new customers or DOSE25 for returning patients, and discover which prescription-only treatment best suits your individual needs and circumstances.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
